Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Posts Earnings Results, Misses Estimates By $0.10 EPS

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.

Lakewood-Amedex Biotherapeutics Trading Down 7.2%

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.02 during mid-day trading on Wednesday, reaching $0.20. 351,517 shares of the stock were exchanged, compared to its average volume of 7,398,063. The company has a market cap of $471,630.00 and a price-to-earnings ratio of -0.04. The firm has a 50-day simple moving average of $0.92 and a 200 day simple moving average of $5.23. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $98.20.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LABT. Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. Finally, HC Wainwright assumed coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They set a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.

View Our Latest Analysis on LABT

Lakewood-Amedex Biotherapeutics Company Profile

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Featured Stories

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.